ATI-502
Total Payments
$16,907
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $16,907 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,907 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO | Aclaris Therapeutics, Inc. | $16,907 | 0 |
Top Doctors Receiving Payments for ATI-502
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Worcester, MA | $16,907 | 1 |
Ad
Manufacturing Companies
- Aclaris Therapeutics, Inc. $16,907
Product Information
- Type Drug
- Total Payments $16,907
- Total Doctors 0
- Transactions 1
About ATI-502
ATI-502 is a drug associated with $16,907 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Aclaris Therapeutics, Inc..
Payment data is available from 2018 to 2018. In 2018, $16,907 was paid across 1 transactions to 0 doctors.
The most common payment nature for ATI-502 is "Unspecified" ($16,907, 100.0% of total).
ATI-502 is associated with 1 research study, including "AN OPEN-LABEL PILOT STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY IN ADULT SUBJECTS WITH NON-SEGMENTAL FACIAL VITILIGO" ($16,907).